About: MMP9 is decreased in natalizumab-treated MS patients at risk for PML   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Fissolo Nicolas, Pignolet Béatrice, Matute-Blanch Clara, Triviño Juan Carlos, Miró Berta, Mota Miriam, Perez-Hoyos Santiago, Sanchez Alex, Vermersch Patrick, Ruet Aurélie, Sèze Jérome, Labauge Pierre, Vukusic Sandra, Papeix Caroline, Almoyna Laurent, Tourbah Ayman, Clavelou Pierre, Moreau Thibault, Pelletier Jean, Lebrun-Frenay Christine, Montalban Xavier, Brassat David, Comabella Manuel, BIONAT BEST-MS, network SFSEP. MMP9 is decreased in natalizumab-treated MS patients at risk for PML. Annals of Neurology, 2017, ⟨10.1002/ana.24987⟩
  • Perez-Hoyos Santiago, Sanchez Alex, Vermersch Patrick, Ruet Aurélie, Sèze Jérome, Labauge Pierre, Vukusic Sandra, Papeix Caroline, Tourbah Ayman, Clavelou Pierre, Moreau Thibault, Pelletier Jean, Lebrun-Frenay Christine, Montalban Xavier, Brassat David, Comabella Manuel. MMP9 is decreased in natalizumab-treated MS patients at risk for PML. Annals of Neurology, 2017, ⟨10.1002/ana.24987⟩
Title
  • MMP9 is decreased in natalizumab-treated MS patients at risk for PML
dc:date
  • 2017
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software